BOSTON (FINALLY) — I slept little, ate poorly, drank moderately, and didn’t exercise, save for a single walk up a big hill with Luke Timmerman. I attended meetings, presentations, and breakouts. It rained a lot. I talked to lots of people. I was asked, “How’s your meeting going?” 7,568 times. I wrote some words and tweeted. I lived in a rented house with six STAT co-workers and brewed an insane amount of coffee.

I flew to San Francisco with some burning biotech questions on my mind. Now that the J.P. Morgan Healthcare Conference 2018 is in the books, here are some of the burning answers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy